It is estimated that in the Kansas City area more than 50,000 adults suffer from clinical depression. In addition, more than 25,000 children and youth have symptoms of depression.
The physicians at PAKC are constantly searching for innovative treatments for these patient populations. Soon, PAKC will offer two additional therapies for the treatment of depression—Ketamine and TMS (Transcranial Magnetic Stimulation).
These leading-edge approaches require specialized expertise and equipment, which will be offered at a new, dedicated suite at our Leawood location. We believe that we will be the first psychiatric practice in the region, and one of just a few in the country, to offer Ketamine and TMS treatments for depression.
For patients with major depression, antidepressant medication is commonly the first treatment. Because these antidepressants are only effective in about two out of three patients, our physicians will soon be prescribing new, yet proven, alternative medications as needed. These new medications are called Glutamate Receptor Modulators, which include the drug Ketamine.
Ketamine services will be provided in conjunction with the physician anesthesiologists of Mobile Anesthesia Care of Kansas City.
In addition, our PAKC physicians will soon offer another promising non-invasive treatment. In 2008, the FDA approved the use of Transcranial Magnetic Stimulation (TMS) in certain cases where patients have not responded to antidepressant medication.
Research has found that stimulation of neuromuscular tissue can help in treatment of some cases of depression. TMS uses magnetic waves to stimulate or inhibit nerve response, and induce electrical currents in target sections of the cortex, spinal roots and peripheral nerves.
Please check back periodically for updates, including educational material regarding both Ketamine and TMS.